Cadila Healthcare Limited Sirolimus Export Data — India (DGFT 2022–2026)

Name: Cadila Healthcare Limited Sirolimus Export Records India — #3 Exporter, 5 Shipments, $250.0K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus
Published: 2026-04-01T00:00:00Z
License: https://transdatanexus.com/terms-and-conditions

Suresh Sormare

Sirolimus

India Pharmaceutical Trade Intelligence

$14.9M97 Suppliers48 CountriesHS 30049099

ExportsIndia → UNITED STATES97.5%India → VENEZUELA0.5%

ImportsUNITED STATES → India$67.2K BRAZIL → India$49.9K

#1 Supplier: ZYDUS LIFESCIENCES #1 Buyer: EVERSANA LIFE

Cadila Healthcare Limited — Sirolimus Exporter #3 | $250.0K Trade Value | TransData Nexus | TransData Nexus

Cadila Healthcare Limited — Sirolimus Exporter Profile

Indian Pharmaceutical Exporter · #3 for Sirolimus · $250.0K export value · DGFT Verified

Cadila Healthcare Limited is the #3 Indian exporter of Sirolimus with $250.0K in export value and 5 verified shipments. Cadila Healthcare Limited holds a 1.7% market share in Sirolimus exports across 1 countries. The company exports 41 pharmaceutical products worth $34.9M across 17 therapeutic categories.

Cadila Healthcare Limited — Sirolimus Export Profile: Buyers & Destinations

Cadila Healthcare Limited Sirolimus export treemap — buyers and destination countries | TransData Nexus

Where Does India Export Sirolimus?

Country	Value	Shipments	Share
UNITED STATES	$7.5M	150	95.4%
VENEZUELA	$70.2K	10	0.9%
SWITZERLAND	$62.7K	480	0.8%
IRELAND	$54.7K	6	0.7%

Who Are the Top Buyers of Sirolimus from India?

Buyer	Country	Value	Orders
ASCEND LABORATORIES,LLC	UNITED STATES	$1.8M	36
EVERSANA LIFE SCIENCE SERVICES	UNITED STATES	$1.6M	33
ASCEND LABORATORIES LLC	UNITED STATES	$550.0K	11
DR REDDYS LABORATORIES INC	UNITED STATES	$350.0K	7
SMALL ANIMAL CLINICAL SERVICES	UNITED STATES	$178.3K	12
GLENMARK PHARMACEUTICALS INC	UNITED STATES	$156.9K	4
XX RXXDYSXXABOXXTORXXS IXX	UNITED STATES	$150.0K	3
ASCEND LABORATORIESLLC	UNITED STATES	$128.6K	3
ASCEND LABORATORIES, LLC,	UNITED STATES	$102.8K	3
EVERSANA LIFE SCIENCES SERVICESLLC	UNITED STATES	$100.0K	2

India's Sirolimus is purchased by 128 buyers worldwide. The top buyer is ASCEND LABORATORIES,LLC (UNITED STATES), followed by EVERSANA LIFE SCIENCE SERVICES and ASCEND LABORATORIES LLC.

How Does Cadila Healthcare Limited Compare to Nearest Sirolimus Exporters?

Exporters ranked immediately above and below #3 by export value

#	Supplier	Export Value	Shipments	Countries	Avg/Shipment
1	ZYDUS LIFESCIENCES LIMITED	$1.6M	32	2	$50.0K
4	DR REDDYS LABORATORIES LIMITED	$400.0K	8	1	$50.0K
3	CADILA HEALTHCARE LIMITED ★	$250.0K	5	1	$50.0K
8	GLENMARK PHARMACEUTICALS LIMITED	$214.5K	32	2	$6.7K
5	DR REDDY S LABORATORIES LIMITED	$200.0K	4	1	$50.0K

Cadila Healthcare Limited ranks #3 among 97 Indian Sirolimus exporters. Average shipment value of $50.0K compared to the market average of $62.9K. The closest competitors by value are ZYDUS LIFESCIENCES LIMITED and DR REDDYS LABORATORIES LIMITED.

Which Indian Ports Ship Sirolimus Exports?

Port	Shipments	% Share
DELHI AIR CARGO ACC (INDEL4)	384	30.9%
DELHI AIR	234	18.8%
SAHAR AIR CARGO ACC (INBOM4)	185	14.9%
SAHAR AIR	95	7.6%
Delhi Air	64	5.1%
NHAVA SHEVA SEA (INNSA1)	36	2.9%
AHEMDABAD AIR	29	2.3%
Bombay Air	25	2.0%

Geopolitical & Trade Policy Impact on Cadila Healthcare Limited's Sirolimus Exports

The current geopolitical landscape presents both challenges and opportunities for Indian pharmaceutical exporters like Zydus. The escalating conflict in the Middle East has disrupted key maritime routes, particularly the Red Sea and Suez Canal, leading to longer transit times and increased freight costs. Major carriers have suspended or restricted transits, extending transit times by 10–20 days and raising freight rates by 40–50% on key India–Europe routes. (livemint.com) This situation poses significant challenges for time-sensitive pharmaceutical shipments, especially temperature-sensitive medicines. (economictimes.indiatimes.com)

Conversely, U.S.–China trade tensions have prompted the U.S. to impose tariffs on Chinese pharmaceutical imports, creating an opportunity for Indian exporters to fill the supply gap. However, the U.S. has also introduced tariffs on Indian imports, including a 25% "reciprocal" tariff, followed by an additional 25% penalty tied to India's continued imports of Russian oil, bringing the total duty to 50%. (en.wikipedia.org) While pharmaceuticals are currently exempt, the potential for future tariffs necessitates strategic planning.

In the European Union, compliance with the Falsified Medicines Directive (FMD) is crucial. The FMD mandates stringent serialization and traceability requirements to prevent counterfeit medicines from entering the supply chain. Non-compliance can result in restricted market access, making adherence to these regulations imperative for exporters like Zydus.

Cadila Healthcare Limited — Regulatory Compliance & Quality Standards

Maintaining compliance with international regulatory standards is paramount for Indian pharmaceutical exporters. The U.S. FDA, WHO, and EU Good Manufacturing Practice (GMP) guidelines set stringent quality benchmarks. Any lapses can lead to import alerts, product recalls, or facility shutdowns. For instance, in 2019, Zydus's Moraiya facility received an Official Action Indicated (OAI) classification from the U.S. FDA, indicating that regulatory and/or administrative actions were recommended. (moneycontrol.com) Such events underscore the importance of robust quality assurance systems.

The evolving regulatory landscape demands continuous investment in compliance infrastructure. The EU's Falsified Medicines Directive and the U.S. Drug Supply Chain Security Act (DSCSA) require advanced serialization and traceability measures. Non-compliance can result in restricted market access, making adherence to these regulations imperative for exporters like Zydus.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Analysis Methodology

1.Product Matching: Sirolimus shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
2.Supplier Identification: Cadila Healthcare Limited matched across shipments using name normalization, accounting for company name formatting variations.
3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.

Government-Sourced Data

Official DGFT customs records

Transparent Methodology

Calculations fully disclosed above

Global Coverage

Exports to 48+ countries, 128+ buyers

Expert-Reviewed

Analyzed by pharmaceutical trade specialists

Sirolimus

Sirolimus

Cadila Healthcare Limited — Sirolimus Exporter Profile

Cadila Healthcare Limited — Sirolimus Export Profile: Buyers & Destinations

Where Does India Export Sirolimus?

Who Are the Top Buyers of Sirolimus from India?

What Is India's Total Sirolimus Export Value and How Much Does Cadila Healthcare Limited Contribute?

What Is the Average Shipment Value for Cadila Healthcare Limited's Sirolimus Exports?

How Does Cadila Healthcare Limited Compare to Other Indian Sirolimus Exporters?

Regulatory Requirements: Exporting Sirolimus to Key Markets

United States — FDA

How Does Cadila Healthcare Limited Compare to Nearest Sirolimus Exporters?

Which Indian Ports Ship Sirolimus Exports?

What Other Immunosuppressants Products Does Cadila Healthcare Limited Export?

Geopolitical & Trade Policy Impact on Cadila Healthcare Limited's Sirolimus Exports

Cadila Healthcare Limited — Regulatory Compliance & Quality Standards

About Cadila Healthcare Limited

Market Intelligence

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Primary Data Source

Analysis Methodology

Get Sirolimus Export Data from Cadila Healthcare Limited

Sirolimus Stats

Company Overview

Top Products by Cadila Healthcare Limited

Related Analysis

Need Detailed Export Data?

Data Source